Clarivate Plc Website

Clarivate Plc

NYSE-CLVT

Company Overview

Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.

  • Name

    Clarivate Plc

  • CEO

    Matitiahu Shem Tov

  • Website

    www.clarivate.com

  • Sector

    Professional Services

  • Year Founded

    1864

Company Statistics

Profile

  • Market Cap

    —

  • EV

    —

  • Shares Out

    —

  • Revenue

    —

  • Employees

    —

Margins

  • Gross

    —

  • EBITDA

    —

  • Operating

    —

  • Pre-Tax

    —

  • Net

    —

  • FCF

    —

Returns (5Yr Avg)

  • ROA

    —

  • ROTA

    —

  • ROE

    —

  • ROCE

    —

  • ROIC

    —

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    —

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    —

  • Net Debt

    —

  • Debt/Equity

    —

  • EBIT/Interest

    —

Growth (CAGR)

  • Rev 3Yr

    —

  • Rev 5Yr

    —

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    —

  • Dil EPS 5Yr

    —

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    —

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Bulls Say

  • Clarivate's market-leading products such as Web of Science and Derwent have high customer loyalty.

  • A successful turnaround in the company’s organic-growth profile should result in a meaningful expansion in its valuation multiples.

  • After many years of underinvestment, Clarivate is now investing again in its core products, which should boost growth.

Bears Say

  • Clarivate is losing market share in some of its key markets as underinvestment has allowed competitors to take advantage of new market opportunities.

  • The company has high financial leverage that limits capital allocation opportunities such as acquisitions and dividends.

  • Macroeconomic issues have had an impact on performance in its current strategic period, making it difficult to gain confidence in underlying business improvement.

Source: Morningstar Analysis - Oct 30, 2025

What's happening

Nov 12, 2025 - Dec 12, 2025

Clarivate PLC Faces Challenges Amidst Innovation Efforts

  • Clarivate launched the Derwent Patent Monitor to enhance intellectual property evaluations through AI.
  • The company published reports highlighting innovation in women's health and recognized influential researchers globally.
  • Despite these initiatives, stock performance declined due to external pressures and analyst downgrades.

Over the past month, Clarivate PLC (CLVT) experienced a slight decline of 0.3%. This underperformance is notably lower than the S&P 500's gain of 0.7%, indicating a relative underperformance of -1.0% against this benchmark. Analyst sentiment has been cautious, as RBC Capital's Ashish Sabadra revised CLVT’s price target down from $6.00 to $5.00 amid prevailing market conditions that have affected investor confidence.

In an effort to bolster its position in the intellectual property sector, Clarivate launched the Derwent Patent Monitor on November 24. This innovative software aims to improve patent evaluations by replacing traditional methods with project-based workflows and real-time feedback mechanisms; however, it did not lead to immediate positive movement in stock prices.

The company's commitment to addressing significant societal issues was evident through its "Companies to Watch" report released on November 13, which highlighted startups innovating in women's health sectors such as reproductive care and mental health while emphasizing inclusivity in clinical research—a theme resonant within current healthcare discussions. Despite these efforts being well-received conceptually, they coincided with mixed reactions from investors regarding overall business performance.

Additionally, on November 12, Clarivate recognized influential researchers worldwide by releasing its Highly Cited Researchers list, celebrating those whose work has significantly impacted their fields across various countries. Although these initiatives reflect positively on CLVT's brand image and commitment to innovation within academia and industry alike, they failed to generate substantial momentum for stock recovery during this period.

Overall trends indicate that while there were notable efforts towards innovation and recognition within key sectors like healthcare and research analytics, external pressures—including analyst downgrades—overshadowed these developments leading CLVT’s performance downward relative both to the S&P 500 index as well as underperforming against the Industrials (XLI) sector by -2.6%.

NYSE:CLVT